Epigenetic measures based on DNA methylation are currently the strongest single predictors of biological aging in adults. Steve Horvath University of California Los Angeles developed the first multi-tissue epigenetic clock showing that specific methylation patterns across the genome track chronological age and are associated with mortality and disease risk. Morgan Levine Yale School of Medicine extended that approach by combining clinical biomarkers with methylation to create PhenoAge, which better predicts morbidity and functional decline than chronological age alone. These methylation-based clocks capture cumulative molecular changes across cell types and are reproducible across cohorts, making them central to contemporary aging research.
Other molecular and cellular predictors
Telomere length was an early biomarker of interest because of its tie to cellular replication, but population studies and meta-analyses indicate it is a weaker, more variable predictor of systemic aging than epigenetic measures. Proteomic and metabolomic signatures are emerging as complementary predictors: panels of circulating proteins and metabolites can reflect organ-system dysfunction and predict near-term health outcomes. Researchers such as Daniel W. Belsky Columbia University have quantified a Pace of Aging metric using longitudinal organ-system biomarkers, showing that trajectories of multiple physiological systems provide a clinically meaningful measure of biological aging. Inflammation markers such as C-reactive protein and measures of immune aging also add predictive value for disease and functional decline.
Relevance, causes, and consequences
These biomarkers are relevant because they link molecular change to real-world outcomes: accelerated epigenetic age and adverse proteomic profiles are associated with earlier onset of chronic disease, disability, and mortality. Causes of accelerated biomarker aging include environmental exposures, chronic psychosocial stress, and socioeconomic disadvantage; work by Elissa Epel University of California San Francisco illustrates how chronic stress correlates with biological aging indicators. Consequences extend beyond individual health to health-care planning and public health policy: reliable biomarkers can identify high-risk groups for preventive interventions and allow objective assessment of anti-aging therapies.
Nuances and limitations include population specificity of many clocks, differences in tissue sampling, and limited validation in diverse global populations. Combining multi-omics, clinical measures, and longitudinal physiological assessment currently offers the best predictive approach, but equitable application requires broader validation across cultural and territorial contexts to avoid biased risk estimates.